Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
Key facts
- Who runs it
- Humanity and Health Research Centre
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 138 people enrolled
- Started
- 15 May 2015
- Ended
- 31 Oct 2024
- Type of study
- Interventional, 8 groups
- Treatments tested
- PR4 + LDV/SOF + ASV 4 wk
- PR4 + LDV/SOF + SMV 4 wk
- PR4 + LDV/SOF + ASV 6 wk
- PR4 + LDV/SOF + SMV 6 wk
- PR4 + LDV/SOF + ASV 8 wk
- PR4 + LDV/SOF + SMV 8 wk
- PR4 + LDV/SOF + ASV 12 wk
- PR4 + LDV/SOF + SMV 12 wk
- Record updated
- 26 March 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Individuals with chronic HCV GT1b infection
- HCV RNA ≥ 10000 IU/mL at screening
- Received 4 weeks pegylated interferon plus ribavirin (PR4) therapy and are intolerant to PR4
- Cirrhosis determination; a liver biopsy may be required
- Use of highly effective contraception methods if female of childbearing potential or sexually active male
Who cannot take part
- Active or recent history (≤ 1 year) of drug or alcohol abuse
- HIV or HBV co-infection
- History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate
- Pregnant or nursing female or male with pregnant female partner
- Hematologic or biochemical parameters at Screening outside the protocol- specified requirements
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are interferon/ribavirin-intolerant.
The 8 groups in the trial
- PR4 + LDV/SOF + ASV 4 wkTreatment being tested
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.
- PR4 + LDV/SOF + SMV 4 wkTreatment being tested
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.
- PR4 + LDV/SOF + ASV 6 wkTreatment being tested
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.
- PR4 + LDV/SOF + SMV 6 wkTreatment being tested
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.
- PR4 + LDV/SOF + ASV 8 wkTreatment being tested
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \> 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.
- PR4 + LDV/SOF + SMV 8 wkTreatment being tested
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \> 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.
- PR4 + LDV/SOF + ASV 12 wkTreatment being tested
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.
- PR4 + LDV/SOF + SMV 12 wkTreatment being tested
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)
- Record updated
- 26 March 2025